<i id='C5C5F218CD'><strike id='C5C5F218CD'><tt id='C5C5F218CD'><pre id='C5C5F218CD'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
BioMarin wins approval for gene therapy to treat hemophilia A 
Alabama IVF ruling threatens families facing fatal genetic disease 
Affirmative action in medical school literally saved lives 
Novo Nordisk touts Wegovy study, but still struggling with supply 
Activists slam private health insurers over coverage restrictions 
A solution to the after 
Walensky prepares to leave CDC — and Congress — behind 
Idaho college killings prosecutors challenge defense's grand jury claims 
Bright Health sells Medicare Advantage business to Molina 
Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma 
Heart attack and stroke risk calculators need revising 
Why palliative psychiatry is worth discussing 
Biden outlines 'new path' to provide student loan relief after Supreme Court rejection 
Ed Silverman on new gene therapies, biosimilars, coffee, and more 
Trump demands the U.S. pay no more for drugs than other countries … again 
